Divis Laboratories Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Divis Laboratories Q2 results FY27 announcement is the next scheduled earnings event for Divi’s Laboratories Ltd., a Hyderabad-based pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), custom synthesis products and generic intermediates for global drugmakers. The stock traded at Rs 9,255.00 on the NSE on 15 September 2026, down 0.72% from the previous close of Rs 9,322.00, about 3.7% below its 52-week high of Rs 9,615.00 and 64.2% above its 52-week low of Rs 5,636.50.

What makes the Divis Laboratories Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 2,660.00 crore of revenue and a profit of Rs 696.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 2,974.00 crore and a profit of Rs 891.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Divis Laboratories Q2 Results FY27 Date?

The Divis Laboratories Q2 results date for FY27 is not confirmed. As of 15 September 2026, Divi’s Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Divis Laboratories Q2 results date becomes public through that filing rather than through any advance announcement.

The Divis Laboratories Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Divi’s Laboratories.

Divis Laboratories Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Divis Laboratories Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Divi’s Laboratories. The Divis Laboratories Q2 results watchlist below is built from what the company has actually reported and disclosed.

Divi’s Laboratories has posted a steady climb in revenue over the last five quarters, from Rs 2,357 crore in Jun25 to Rs 2,974 crore in Jun26, with operating margin also moving up from 32% to 42% over the same stretch. Investors will be watching whether the September 2026 quarter sustains the Jun26 momentum in both top line and margin, or whether that quarter’s sharp margin jump proves harder to repeat.

Other income at Divi’s has swung considerably from quarter to quarter, at Rs 119 crore in Jun25, Rs 146 crore in Sep25, dropping to just Rs 13 crore in Dec25, back up to Rs 154 crore in Mar26, and then Rs 63 crore in Jun26. Because this non-operating item has moved independently of the underlying business, net profit figures of Rs 557 crore, Rs 696 crore, Rs 598 crore, Rs 756 crore and Rs 891 crore across these quarters partly reflect this swing rather than operating performance alone, something to keep in mind when comparing the September 2026 quarter’s net profit to prior periods.

Operating margin stepped up sharply to 42% in Jun26 compared with a 32-35% range in the four quarters before it, a level worth watching to see if it holds, moderates, or was influenced by a favourable product or currency mix in that specific quarter. Given operating profit also rose from Rs 743 crore in Jun25 to Rs 1,240 crore in Jun26, the September 2026 quarter’s operating profit and margin trend will be a key reference point for readers tracking the company’s underlying manufacturing performance.

Check Divi’s Laboratories Ltd. Live Fundamentals on the Univest Screener

Divis Laboratories Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Divi’s Laboratories Ltd. reported revenue of Rs 2,974.00 crore in Q1 FY27, up 26.18% from Rs 2,357.00 crore in Q1 FY26, and a profit of Rs 891.00 crore at the net level, up 59.96% from Rs 557.00 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was up 6.48% over the March 2026 quarter figure of Rs 2,793.00 crore, and net profit was up 17.86% from Rs 756.00 crore in Q4 FY26. Operating margin stood at 42.0% in Q1 FY27 against 34.0% in the September 2025 quarter, which is the comparison the Divis Laboratories Q2 results print will be read against.

Q2 FY26 Base: The Comparison Divis Laboratories Q2 Results FY27 Must Beat

Divi’s Laboratories Ltd. reported revenue of Rs 2,660.00 crore and a profit of Rs 696.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Divis Laboratories Q2 results preview.

Net profit in that base quarter was below the Rs 891.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 2,660.00 crore sits below the Rs 2,974.00 crore of the June 2026 quarter, which frames how much sequential movement the Divis Laboratories Q2 results print needs to show growth.

Divi’s Laboratories Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	2,660.00	696.00
Q3 FY26 (Dec 2025)	2,578.00	598.00
Q4 FY26 (Mar 2026)	2,793.00	756.00
Q1 FY27 (Jun 2026)	2,974.00	891.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Divis Laboratories Q2 results preview uses.

Revenue across those four quarters ranged from Rs 2,578.00 crore to Rs 2,974.00 crore, and net profit from Rs 598.00 crore to Rs 891.00 crore. That spread is the honest context for the Divis Laboratories Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Divis Laboratories Q2 Results FY27

The Divis Laboratories Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Divi’s Laboratories has already reported.

Valuation Sits Well Above Historical Norms

Divi’s Laboratories trades at a trailing P/E of about 82.6 and a price-to-book ratio of roughly 14.7, against a return on equity of 16.8% and negligible debt (debt-to-equity near 0.00). These are factual valuation and balance-sheet readings as of the current market price of Rs 9,255, not an assessment of whether the stock is fairly priced.

Stock Trades Near Recent Highs

The stock’s 52-week range spans Rs 5,636.5 to Rs 9,615, with the current price of Rs 9,255 sitting well above both its 50-day moving average of Rs 8,252.74 and its 200-day moving average of Rs 6,858.27. An RSI reading of 62.68 places it in a moderately elevated zone, a technical detail worth noting ahead of results.

Other Income Volatility Clouds Profit Trend

With other income ranging from as low as Rs 13 crore to as high as Rs 154 crore across the last five quarters, readers comparing net profit across periods should separate this non-operating swing from the operating profit trend, which has moved more steadily from Rs 743 crore to Rs 1,240 crore over the same period.

Divis Laboratories Q2 Results FY27: Share Price and Valuation Going Into the Print

Divi’s Laboratories share price today is Rs 9,255.00 on the NSE, down Rs 67.00 or 0.72% from the previous close of Rs 9,322.00 on 15 September 2026, ahead of the Divis Laboratories Q2 results announcement.

Metric	Value (15 September 2026)
NSE Symbol	DIVISLAB
Current Market Price	Rs 9,255.00
52-Week High	Rs 9,615.00
52-Week Low	Rs 5,636.50
Market Capitalisation	Rs 2,47,470 crore
PE Ratio	82.60
PB Ratio	14.71
EPS (TTM)	Rs 112.05
Book Value per Share	Rs 629.00
Debt to Equity	0.00
Return on Equity	16.8%
50-Day Moving Average	Rs 8252.74
200-Day Moving Average	Rs 6858.27
RSI (14)	62.68

The stock trades above both its 50-day average of Rs 8252.74 and its 200-day average of Rs 6858.27, with a 14-day RSI of 62.68. None of this is a view on where the shares go once the Divis Laboratories Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Divi’s Laboratories Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Divis Laboratories Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Divis Laboratories Q2 results print in proportion.

1. Revenue against the Rs 2,660.00 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 696.00 crore in that same quarter
3. Operating margin against 42.0% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Divis Laboratories Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Divis Laboratories Q2 Results FY27

The Divis Laboratories Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Divi’s Laboratories Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Divis Laboratories Q2 results FY27 print faces a base of Rs 2,660.00 crore in revenue and a profit of Rs 696.00 crore, with the most recent quarter having delivered Rs 2,974.00 crore and a profit of Rs 891.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Divi’s Laboratories, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Divis Laboratories Q2 Results FY27

What is the Divis Laboratories Q2 results date for FY27?

Ans. The Divis Laboratories Q2 results date for FY27 is not confirmed. Divi’s Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Divis Laboratories Q2 results 2026 cover?

Ans. The Divis Laboratories Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Divi’s Laboratories Ltd. reports revenue, operating profit and net profit for that period, and the Divis Laboratories Q2 results filing also carries the notes to the accounts.

What were the Divi’s Laboratories Q1 FY27 results?

Ans. Divi’s Laboratories Ltd. reported revenue of Rs 2,974.00 crore in Q1 FY27 and a profit of Rs 891.00 crore at the net level. Revenue was up 26.18% versus Q1 FY26 and net profit was up 59.96% from Rs 557.00 crore in Q1 FY26.

What were Divi’s Laboratories Q2 FY26 results in the September 2025 quarter?

Ans. Divi’s Laboratories Ltd. reported revenue of Rs 2,660.00 crore and a profit of Rs 696.00 crore in Q2 FY26. Operating margin was 34.0%. Those figures form the base for the Divis Laboratories Q2 results FY27 comparison.

What are the main Divis Laboratories Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Divis Laboratories Q2 results expectations centre on revenue against the Rs 2,660.00 crore base, net profit against a profit of Rs 696.00 crore, operating margin against 42.0% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Divi’s Laboratories share price today ahead of the Q2 earnings?

Ans. Divi’s Laboratories share price is Rs 9,255.00 on the NSE as of 15 September 2026, down 0.72% from Rs 9,322.00. The stock is about 3.7% below its 52-week high of Rs 9,615.00 and 64.2% above its 52-week low of Rs 5,636.50, at a market capitalisation of Rs 2,47,470 crore.

Is Divi’s Laboratories a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Divi’s Laboratories Ltd. The stock trades at a price-to-book ratio of 14.71 with a return on equity of 16.8%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.